- Home
- LLY
as 08-01-2025 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Upcoming Earnings Alert:
Get ready for potential market movements as Eli Lilly and Company LLY prepares to release earnings report on 07 Aug 2025.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 652.7B | IPO Year: | N/A |
| Target Price: | $1015.65 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 12.29 | EPS Growth: | 80.99 |
| 52 Week Low/High: | $677.09 - $972.53 | Next Earning Date: | 08-07-2025 |
| Revenue: | $49,003,200,000 | Revenue Growth: | 36.38% |
| Revenue Growth (this year): | 34.53% | Revenue Growth (next year): | 19.44% |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Motley Fool
6 hours ago
3 Unstoppable Stocks to Buy in August
Motley Fool
18 hours ago
Why Eli Lilly Stock Topped the Market Today
Yahoo Finance Video
19 hours ago
Earnings, Fed commentary, consumer credit: What to Watch
Investor's Business Daily
19 hours ago
Stock Market Week Ahead: Caterpillar, Palantir And Black Hat Week
Bloomberg
20 hours ago
Stocks Sink as Bonds Jump on Deepening Jobs Cracks: Markets Wrap
MT Newswires
20 hours ago
S&P 500 Posts Weekly Decline as Payrolls Data Misses Expectations
MT Newswires
21 hours ago
Sector Update: Health Care Stocks Gain Late Afternoon
MT Newswires
21 hours ago
Eli Lilly Shares Rise After US Health Officials Reportedly Consider Weight-Loss Drugs for Medicaid Coverage
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.